首页> 外文期刊>Journal of the American Chemical Society >A Multistage Pathway for Human Prion Protein Aggregation in Vitro: From Multimeric Seeds to β-Oligomers and Nonfibrillar Structures
【24h】

A Multistage Pathway for Human Prion Protein Aggregation in Vitro: From Multimeric Seeds to β-Oligomers and Nonfibrillar Structures

机译:人Pri蛋白体外聚集的多阶段途径:从多聚种子到β-寡聚体和非原纤维结构。

获取原文
获取原文并翻译 | 示例
       

摘要

Aberrant protein aggregation causes numerous neurological diseases including Creutzfeldt-Jakob disease (CJD), but the aggregation mechanisms remain poorly understood. Here, we report AFM results on the formation pathways of β-oligomers and nonfibrillar aggregates from wild-type full-length recombinant human prion protein (WT) and an insertion mutant (10OR) with five additional octapeptide repeats linked to familial CJD. Upon partial denaturing, seeds consisting of 3-4 monomers quickly appeared. Oligomers of ~11-22 monomers then formed through direct interaction of seeds, rather than by subsequent monomer attachment All larger aggregates formed through association of these β-oligomers. Although both WT and 10OR exhibited identical aggregation mechanisms, the latter oligomerized faster due to lower solubility and, hence, thermodynamic stability. This novel aggregation pathway has implications for prion diseases as well as others caused by protein aggregatioa
机译:异常的蛋白质聚集会引起许多神经系统疾病,包括Creutzfeldt-Jakob病(CJD),但对聚集机制的了解仍然很少。在这里,我们报告AFM结果从野生型全长重组人病毒蛋白(WT)和插入突变体(10OR)与家族CJD的五个额外八肽重复的β-寡聚体和非原纤维聚集体的形成途径。部分变性后,迅速出现由3-4个单体组成的种子。然后〜11-22单体的低聚物是通过种子的直接相互作用而不是随后的单体附着形成的。所有较大的聚集体都是通过这些β-低聚物的缔合而形成的。尽管WT和10OR均表现出相同的聚集机理,但后者的溶解度和热力学稳定性均较低,因此其低聚反应更快。这种新颖的聚集途径对病毒疾病以及由蛋白质聚集引起的其他疾病具有影响

著录项

  • 来源
    《Journal of the American Chemical Society》 |2011年第22期|p.8586-8593|共8页
  • 作者单位

    Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California 94550, United States,Department of Materials Science and Engineering, University of California, Los Angeles, Los Angeles, California 90095, United States;

    Department of Materials Science and Engineering, University of California, Los Angeles, Los Angeles, California 90095, United States;

    Department of Pathology, Case Western Reserve University, Cleveland, Ohio 44106, United States;

    Department of Pathology, Case Western Reserve University, Cleveland, Ohio 44106, United States;

    Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California 94550, United States;

    Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California 94550, United States;

    Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, California 90033, United States;

    Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, California 90033, United States;

    Department of Pathology, Case Western Reserve University, Cleveland, Ohio 44106, United States;

    Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California 94550, United States,Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 03:14:16

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号